Sector News

Merck to lay off about 1,800 U.S. sales reps in cost-cutting

October 23, 2017
Life sciences

Merck & Co. said Friday it is laying off about 1,800 U.S. sales representatives, or nearly 7% of the drugmaker’s U.S. workforce, in a reorganization the company says will cut costs and shift focus to products with growth potential.

Merck is eliminating three sales teams comprising reps who promote drugs to primary-care doctors, endocrinologists and drugs used in hospitals.

At the same time, Merck said it would create a new “chronic care” sales team of 960 reps who will promote its top-selling drug, diabetes treatment Januvia, plus insomnia medication Belsomra and drugs for respiratory diseases and women’s health. Merck also hopes to begin selling two new diabetes drugs if regulators approve them.

Employees being laid off can apply for the new sales positions or other open jobs at Merck, said spokeswoman Claire Gillespie.

Merck said the changes are “part of ongoing companywide efforts to sharpen Merck’s focus on innovative R&D that addresses significant unmet medical needs and on our best opportunities for growth, while reducing overall costs.”

By Peter Loftus

Source: MarketWatch

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.